|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemophilia is a rare bleeding disorder caused by a deficiency of the plasma coagulation factors VIII and IX (hemophilia A [HA] and hemophilia B [HB], respectively).
|
31669933 |
2020 |
|
Hemophilia B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the remaining 9504 patients still being followed up, 5748 (60.5%) had haemophilia A, 1300 (13.7%) haemophilia B, 1980 (20.8%) von Willebrand Disease while 476 (5.0%) had another clotting factor deficiency (Factor I, II, V, combined V and VIII, VII, X, XI and XIII).
|
30515664 |
2019 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Haemophilia is a hereditary X-linked recessive disorder caused by a deficiency of either clotting factor VIII (haemophilia A) or IX (haemophilia B).
|
30962210 |
2019 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of those cases, 456 (64.8%) had factor VIII and 248 (35.2%) had factor IX deficiency.
|
30924993 |
2019 |
|
Hemophilia B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hemophilia A and Hemophilia B are the most common of the severe bleeding disorders and are caused by a deficiency in blood clotting factor VIII or factor IX respectively.
|
31421983 |
2019 |
|
Hemophilia B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, they review the current knowledge on the effect of exercise on specific coagulation factors as well as on global coagulation and demonstrate that exercise increases factor VIII levels in healthy persons, all persons with hemophilia B (HB) and in persons with mild and moderate hemophilia A (HA).
|
30357762 |
2018 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of these mutational profiles in <i>F8</i> and <i>F9</i> genes among Malaysian patients will provide a useful reference for the early detection and diagnosis of HA and HB in the Malaysian population.
|
30210749 |
2018 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mean weekly dose of factor VIII in severe HA was 84 international units/kg/wk (IU/kg/wk) vs 71 IU/kg/wk of factor IX in severe HB.
|
29314552 |
2018 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infusion of bypassing agents, such as recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin complex concentrate, are suggested as alternative therapies to factor VIII (haemophilia A) or IX (haemophilia B) for individuals who no longer respond to these treatments because they develop inhibitory antibodies.
|
28944952 |
2017 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The best currently available treatments for hemophilia A and B (factor VIII or factor IX deficiency, respectively) require frequent intravenous infusion of highly expensive proteins that have short half-lives.
|
28895852 |
2017 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deficiencies of blood coagulation factors VIII and IX (haemophilia A and haemophilia B) represent the most common inherited bleeding disorders with a wide range of causative mutations.
|
25255241 |
2015 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the recent results in haemophilia B are extremely encouraging, there is, as yet, no similar data for factor VIII gene therapy.
|
24762274 |
2014 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemarthrosis, the hallmark of severe hemophilia, is the major cause of serious bleeding events, disability and reduced quality of life in patients with factor VIII or factor IX deficiency.
|
22992238 |
2012 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied 16 patients with severe hemophilia A (factor VIII and factor VIII:Ag <1%) with intron 22 inversions of the factor VIII gene and 6 patients with hemophilia B, 2 each having a common mutation, for the common prothrombotic markers in the anticoagulant and fibrinolytic cascade.
|
18550475 |
2008 |
|
Hemophilia B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Persistent and high levels of factor IX and factor VIII gene expression for treating hemophilia B and A, respectively, were achieved in mouse livers using hydrodynamics-based gene transfer of naked plasmid DNA incorporating these novel gene expression systems.
|
16096011 |
2005 |
|
Hemophilia B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common.
|
12781551 |
2003 |
|
Hemophilia B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hemophilia is the bleeding diathesis caused by mutations in the gene encoding factor VIII (hemophilia A) or factor IX (hemophilia B).
|
12463593 |
2002 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four hundred and seven patients (352 haemophilia A and 55 haemophilia B) were investigated for the presence of factor VIII and IX inhibitors.
|
11380631 |
2001 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sixty probable carriers of haemophilia from 25 families were studied by using coagulation phenotype and DNA analysis: 33 with haemophilia A and 27 with haemophilia B. Coagulation phenotype was based on factor VIII/IX assay and DNA analysis on the examination of restriction fragment length polymorphisms (RFLPs) within and closely linked to factor VIII or IX: 3 RFLP for factor VIII and 3 for factor IX.
|
1982946 |
1991 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess whether these men might also be infected with HTLV-I, we examined the HTLV-I antibody status of 127 factor VIII (hemophilia A) recipients and 71 factor IX (hemophilia B) recipients.
|
2508796 |
1989 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor VIII-deficient patients are treated an average of 18 times per year compared to ten times per year for patients with Factor IX deficiency.
|
6786095 |
1980 |
|
Hemophilia B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The activity of factor IX in a definite carrier of hemophilia B was significantly lower than that of factor VIII in a definite carrier of hemophilia A.3.
|
1036844 |
1976 |